Key result
V2 vasopressin receptor gene transfer boosts local fractional shortening and global contractility in preclinical models.
Why the study?
Systemic AVP levels are increased in congestive heart failure causing reduced cardiac contractility via V1 receptors, and heterologous myocardial expression of V2 receptors could enhance contractility by activating adenylyl cyclase.
Does adenoviral gene transfer of the V2R into the myocardium increase cardiac contractility in vivo in rat or rabbit models?
Does adenoviral gene transfer of the V2R into the myocardium increase cardiac contractility in vivo in rat or rabbit models?
Adenoviral gene transfer of the V2 vasopressin receptor into the myocardium increases cardiac contractility in vivo, suggesting a potential novel strategy for congestive heart failure therapy.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications in HF; leaves open therapeutic potential of V2R gene transfer in humans.
BACKGROUND: Systemic levels of arginine vasopressin (AVP) are increased in congestive heart failure, resulting in vasoconstriction and reduced cardiac contractility via V(1) vasopressin receptors. V(2) vasopressin receptors (V2Rs), which promote activation of adenylyl cyclase, are physiologically expressed only in the kidney and are absent in the myocardium. Heterologous expression of V2Rs in the myocardium could result in a positive inotropic effect by using the endogenous high concentrations of AVP in heart failure. METHODS AND RESULTS: We tested gene transfer with a recombinant adenovirus for the human V2R (Ad-V2R) to stimulate contractility of rat or rabbit myocardium in vivo. Ultrasound-guided direct injection or transcoronary delivery of adenovirus in vivo resulted in recombinant receptor expression in the myocardial target area, leading to a substantial increase in [(3)H]AVP binding. In 50% of the cardiomyocytes isolated from the directly injected area, single-cell shortening measurements detected a significant increase in contraction amplitude after exposure to AVP or the V2R-specific desmopressin (DDAVP). Echocardiography of the target myocardial area documented a marked increase in local fractional shortening after systemic administration of DDAVP in V2R-expressing animals but not in control virus-treated hearts. Simultaneous measurement of global contractility (dP/dt(max)) confirmed a positive inotropic effect of DDAVP on left ventricular function in the Ad-V2R-injected animals. CONCLUSIONS: Adenoviral gene transfer of the V2R into the myocardium increases cardiac contractility in vivo. Heterologous expression of cAMP-forming receptors in the myocardium could lead to novel strategies in the therapy of congestive heart failure by bypassing the desensitized beta-adrenergic receptor-signaling cascade.
No takes yet. Share an insight, caveat, or question.
Weig et al. (2000) studied Congestive heart failure (animal model). Adenoviral gene transfer of the human V2 vasopressin receptor (Ad-V2R) vs. Control virus was evaluated on Cardiac contractility (contraction amplitude, local fractional shortening, and global contractility dP/dt(max)). Adenoviral gene transfer of the V2 vasopressin receptor into rat or rabbit myocardium significantly increased local fractional shortening and global contractility compared to control virus.
Synapse has enriched 10 related papers. Consider them for comparative context: